Our study demonstrated that MSG-treated C57BL/6J mice exhibited a similar liver tissue histopathology to that seen in human NAFLD/NASH; increased body weight and visceral fat weight; and elevated blood glucose, serum insulin, total cholesterol, and ALT levels. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.